TrIPLe: Outcomes of a Trifocal IOL in Post-refractive Patients

Sponsor
Vance Thompson Vision ND (Other)
Overall Status
Recruiting
CT.gov ID
NCT04545073
Collaborator
(none)
200
1
6.7
29.8

Study Details

Study Description

Brief Summary

To compare the prediction error of ORA vs formula for post-LASIK cataract patients when PanOptix IOL was implanted. Using post-operative outcomes to determine if preoperative IOL calculations, including Barrett TK, Barrett Universal II, Hill RBF, ASCRS post-refractive calculator, or intraoperative aberrometry is more accurate when the two methods disagree in patients who have had previous refractive surgery undergo cataract surgery.

Condition or Disease Intervention/Treatment Phase
  • Device: PanOptix

Detailed Description

The study will be non-interventional with data being collected prospectively and retrospectively between at least two surgical sites. All subjects will have previous LASIK and be at least 3 months post op PanOptix implantation. The study will enroll up to 200 patients and a statistical database will be created.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Outcomes of a Trifocal IOL in Post-refractive Patients
Actual Study Start Date :
Oct 9, 2020
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Post-refractive trifocal IOL

Device: PanOptix
Trifocal IOL with ORA in post refractive patients

Outcome Measures

Primary Outcome Measures

  1. To determine if preoperative IOL calculations or intraoperative aberrometry is more accurate when the two methods disagree in patients who have had previous refractive surgery undergo cataract surgery. [Pre-op to 9 month visit]

    Percentage of eyes within +/- .5D of target for each formula and ORA. Overall % of eyes that have a disagreement between the two methods

Secondary Outcome Measures

  1. Post-operative monocular visual acuity [3 to 9 month visit]

    Monocular Uncorrected Distance, Intermediate, Near Visual Acuity

  2. Post-operative best corrected visual acuity [3 to 9 month visit]

    Manifest refraction, Best Corrected Distance Visual Acuity, Distance Corrected Intermediate, and Near Visual Acuity

  3. Post-operative uncorrected visual acuity [3 to 9 month visit]

    Binocular Uncorrected Distance, Intermediate, Near Visual Acuity, Best Corrected Distance Visual Acuity, Distance Corrected Intermediate, Near Visual Acuity

  4. Post-operative visual acuity [3 to 9 month visit]

    Percentage of eyes with Uncorrected Distance Visual Acuity of 20/20 or better, 20/25 or better, and 20/30 or better

  5. Post-operative visual acuity [3 to 9 month visit]

    Percentage of eyes with Uncorrected Corrected Intermediate Visual Acuity and Distance Corrected Intermediate Visual Acuity 20/20 or better, 20/25 or better, and 20/30 or better

  6. Post-operative visual acuity [3 to 9 month visit]

    Percentage of eyes with Uncorrected Distance Near Visual Acuity and Distance Corrected Near Visual Acuity of 20/20 or better, 20/25 or better, and 20/30 or better

  7. Patient's quality of vision and reported side-effects [3 to 9 month visit]

    Patient satisfaction questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Previous myopic refractive surgery

  • At least 3 months post op cataract surgery with a trifocal IOL

Exclusion Criteria:
  • Pre-existing or subsequent eye condition that interferes with accurate data collection (retinal detachment, etc.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vance Thompson Vision ND W. Fargo North Dakota United States 58078

Sponsors and Collaborators

  • Vance Thompson Vision ND

Investigators

  • Principal Investigator: Michael Greenwood, MD, Vance Thompson Vision ND

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Vance Thompson Vision ND
ClinicalTrials.gov Identifier:
NCT04545073
Other Study ID Numbers:
  • IOL-VTV-01
First Posted:
Sep 10, 2020
Last Update Posted:
Oct 19, 2020
Last Verified:
Oct 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2020